CONMED Corp (CNMD) Stock
CNMD has an Alpha Score of 33 out of 100 (poor), computed on Nov 1, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 2 trades in CNMD since 2019: 1 purchase and 1 sale, most recently Nicholas Van Taylor (sale, Mar 25, 2019). 5 of the hedge funds AlphaScala tracks reported CNMD in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $5.74M. Its trailing P/E ratio is 23.4 and its net margin 4.1% (key statistics as of Nov 1, 2026).
What is CNMD's Alpha Score?
How it works →Alpha Score of 33 reflects weak overall profile with weak momentum, weak value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 1, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded CONMED Corp (CNMD)?
Most recent: Nicholas Van Taylor (sale, Mar 25, 2019); records start Feb 15, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Van Taylor R-TX · House | 2019-03-25 | sale | $1k – $15k |
| Van Taylor R-TX · House | 2019-02-15 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all CNMD political trades →Which hedge funds own CNMD?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 175K | $5.74M | +3% |
| Citadel Ken Griffin | 142K | $4.66M | -42% |
| Millennium Management Israel Englander | 115K | $3.75M | +51% |
| Point72 Steve Cohen | 70K | $2.28M | -48% |
| D.E. Shaw David Shaw | 68K | $2.23M | +42% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are CNMD's key statistics?
Key statistics as of Nov 1, 2026
How does CNMD's valuation compare with the Healthcare sector?
| Metric | CNMD | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 23.4 | 28.8 | 113 |
| Net margin | 4.12% | 3.66% | 170 |
| Return on equity | 5.51% | 3.71% | 194 |
| Dividend yield (payers) | 0.74% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
CNMD price chart
Powered by TradingViewWhat does CONMED Corp do?
CONMED Corporation is a global medical technology company that designs, manufactures, and distributes surgical equipment and medical devices for orthopedic and general surgery specialties. The company's orthopedic surgery segment provides products for soft tissue repair, powered resection instruments, and foot and ankle surgery systems. Its general surgery division offers advanced surgical and endoscopic technologies, including the AirSeal insufflation system for minimally invasive procedures, smoke evacuation products, electrosurgical generators, and specialized devices for gastroenterology and pulmonology procedures. CONMED serves healthcare professionals including surgeons and specialists in orthopedics, general surgery, gynecology, thoracic surgery, and related fields across approximately 100 countries. The company operates through sales subsidiaries and distribution networks in major markets including the United States, Europe, Asia Pacific, and other regions. CONMED caters to various healthcare settings ranging from ambulatory surgery centers and endoscopy suites to large hospital systems, focusing on delivering solutions that enhance surgical efficiency and patient outcomes in value-based care environments.